%0 Journal Article
%T Applicability of EU(7)-PIM criteria in cross-national studies in
European countries
%A Blanca Laffon
%A Daniela Fialov¨¢
%A Jan Kost£¿iba
%A Jindra Reissigov¨¢
%A Jovana Brki£¿
%A Ljiljana Tasi£¿
%A Peter Doro
%A Silvia Gre£¿¨¢kov¨¢
%A Solange Costa
%A Soner Dogan
%A Valentina Marinkovi£¿
%A Vanessa Valdiglesias
%J Archive of "Therapeutic Advances in Drug Safety".
%D 2019
%R 10.1177/2042098619854014
%X The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]
%K aged
%K geriatrics
%K PIMs
%K potentially inappropriate medications
%K regulatory measures
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591668/